Top

International Journal of Colorectal Disease

Published in:

01-07-2007 | Original Article

A cost analysis of functional bowel disorders in Iran

Authors: Delnaz Roshandel, Mohammadreza Rezailashkajani, Sepideh Shafaee, Mohammad Reza Zali

Published in: International Journal of Colorectal Disease | Issue 7/2007

Abstract

Background and aims

The objective of this work is to evaluate the health care utilization and cost of different types of functional bowel disorder (FBD) in a population of Iranian patients and compare the costs in consulters and non-consulters.

Materials and methods

A consecutive sample of 1,023 patients in an outpatient gastroenterology clinic in central Tehran were interviewed, using two questionnaires based on the Rome II criteria, from December 2004 to May 2005 to detect FBD patients and to determine the frequency of health resource utilization (physician visit, hospitalization, laboratory tests, imaging studies, and drugs) and productivity loss (days off work or with low functionality) due to FBD symptoms in the past 12 months. Societal perspective was used and cost per person per year was estimated in purchasing power parity dollars (PPP$).

Results

The direct costs (for consulters, non-consulters; data presented in this order) were: irritable bowel syndrome (IBS; $92.04, $1.04), unspecified functional bowel disorder (FBD; $100.94, $0.39), functional constipation ($57.23, $1.04), and functional abdominal bloating ($71.35, $0.63). Indirect costs (for consulters, non-consulters) were: IBS ($811.85, $669.09), unspecified FBD ($705.85, $263.47), functional constipation ($587.48, $97.49), and functional abdominal bloating ($147.88, $38.60). Total yearly costs of IBS and functional constipation for urban adult population of Iran were roughly estimated at 2.94 billion PPP$ and 89.2 million PPP$, respectively.

Conclusions

As proven in developed countries, FBD and especially IBS seem to put a heavy burden on the economy of a developing country like Iran. Further population-based studies are needed for more precise estimations.

Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Supp1 II):II43–II47PubMedCrossRef

Thompson WG, Irvine EJ, Pare P et al (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47(1):225–235 (Jan)PubMedCrossRef

Sperber AD, Shvartzman P, Friger M, Fich A (2005) Unexpectedly low prevalence rates of IBS among adult Israeli Jews. Neurogastroenterol Motil 17(2):207–211 (Apr)PubMedCrossRef

Hoseini-Asl MK, Amra B (2003) Prevalence of irritable bowel syndrome in Shahrekord, Iran. Indian J Gastroenterol 22(6):215–216 (Nov–Dec)PubMed

Dapoigny M, Bellanger J, Bonaz B et al (2004) Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 16(10):995–1001 (Oct)PubMedCrossRef

Badia X, Mearin F, Balboa A et al (2002) Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 20(11):749–758PubMedCrossRef

Dean BB, Aguilar D, Barghout V et al (2005) Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 11(1 Suppl):S17–S26 (Apr)PubMed

Muller-Lissner SA, Pirk O (2002) Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 14(12):1325–1329 (Dec)PubMedCrossRef

Le Pen C, Ruszniewski P, Gaudin AF et al (2004) The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 39(4):336–343 (Apr)PubMedCrossRef

10.

Leong SA, Barghout V, Birnbaum HG et al (2003) The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 163(8):929–935 (Apr 28)PubMedCrossRef

11.

Longstreth GF, Wilson A, Knight K et al (2003) Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 98(3):600–607 (Mar)PubMedCrossRef

12.

Akehurst RL, Brazier JE, Mathers N et al (2002) Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 20(7):455–462PubMedCrossRef

13.

Patel RP, Petitta A, Fogel R et al (2002) The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 35(1):14–20 (Jul)PubMedCrossRef

14.

Levy RL, Von Korff M, Whitehead WE et al (2001) Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 96(11):3122–3129 (Nov)PubMedCrossRef

15.

16.

Pare P, Ferrazzi S, Thompson WG et al (2001) An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 96(11): 3130–3137 (Nov)PubMedCrossRef

17.

Garrigues V, Galvez C, Ortiz V et al (2004) Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol 159(5):520–526 (Mar 1)PubMedCrossRef

18.

Pekmezaris R, Aversa L, Wolf-Klein G et al (2002) The cost of chronic constipation. J Am Med Dir Assoc 3(4):224–228 (Jul–Aug)PubMedCrossRef

19.

Roshandel D, Rezailashkajani M, Shafaee S, Zali MR (2006) Symptom patterns and relative distribution of functional bowel disorders in 1,023 gastroenterology patients in Iran. Int J Colorectal Dis 21(8):814–825PubMedCrossRef

20.

Kwan AC, Bao TN, Chakkaphak S, Chang FY, Ke MY, Law NM, Leelakusolvong S, Luo JY, Manan C, Park HJ, Piyaniran W, Qureshi A, Long T, Xu GM, Xu L, Yuen H (2003) Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 18(7):796–802 (Jul)PubMedCrossRef

21.

Boyce PM, Koloski NA, Talley NJ (2000) Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 95(11):3176–3183 (erratum in Am J Gastroenterol 96(4):1319)PubMedCrossRef

22.

Talley NJ, Zinsmeister AR, Melton LJ 3rd (1995) Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 142(1):76–83 (Jul 1)PubMed

23.

Inadomi JM, Fennerty MB, Bjorkman D (2003) Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18:671–682PubMedCrossRef

24.

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006) Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 24(1):21–37PubMedCrossRef

25.

Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP (1999) The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 13(Suppl A):89A–96APubMed

26.

Ghannadi K, Emami R, Bashashati M et al (2005) Irritable bowel syndrome: an epidemiological study from the west of Iran. Indian J Gastroenterol 24(5):225–226 (Sep–Oct)PubMed

27.

Massarrat S, Saberi-Firoozi M, Soleimani A et al (1995) Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol 7(5):427–433 (May)PubMed

28.

Khoshbaten M, Hekmatdoost A, Ghasemi H, Entezariasl M (2004) Prevalence of gastrointestinal symptoms and signs in northwestern Tabriz, Iran. Indian J Gastroenterol 23(5):168–170 (Sep–Oct)PubMed

29.

Harris LA (2005) Prevalence and ramifications of chronic constipation. Manag Care Interface 18(8):23–30 (Aug)PubMed

Title: A cost analysis of functional bowel disorders in Iran
Authors: Delnaz Roshandel
Mohammadreza Rezailashkajani
Sepideh Shafaee
Mohammad Reza Zali
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 7/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-006-0226-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A cost analysis of functional bowel disorders in Iran

Abstract

Background and aims

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2007

Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma

Intra-abdominal erosion of artificial bowel sphincter reservoir

Strangulation of internal hemorrhoids complicating sclerosing therapy with injection of OC-108 (Zione)

Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer

Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis

Assessment of microsatellite instability in colorectal carcinoma at an Indian center